Making sense: therapy targeting RNA continues to advance.
Volkers
N
N
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D009369:Neoplasms / Q000235:genetics* / Q000628:therapy*; D020319:Oligodeoxyribonucleotides, Antisense / Q000494:pharmacology; D054735:Phosphorothioate Oligonucleotides; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000187:drug effects / Q000235:genetics; D012334:RNA, Neoplasm / Q000187:drug effects*; D013873:Thionucleotides / Q000494:pharmacology
D000970:Antineoplastic Agents; D020319:Oligodeoxyribonucleotides, Antisense; D054735:Phosphorothioate Oligonucleotides; D019253:Proto-Oncogene Proteins c-bcl-2; D012334:RNA, Neoplasm; D013873:Thionucleotides; C108494:ISIS 3521; C089753:alicaforsen